Johnson & Johnson Applies For Emergency Use Authorization For COVID-19 Vaccine

A dose of the Pfizer COVID-19 vaccine in New York, 2020. Johnson & Johnson is the third vaccine candidate to apply for emergency use authorization from the FDA. The vaccine requires a single dose and doesn

The company’s vaccine has shown to be 85% effective against severe forms of the disease. Patients will only need to receive one shot instead of two, as with other vaccines already in use in the U.S.

(Image credit: Mary Altaffer/AP)

A third coronavirus vaccine candidate has requested emergency use authorization from the Food and Drug Administration. Johnson & Johnson submitted its application Thursday for the company’s single-dose inoculation.

In a statement released Thursday, the company said if emergency use is granted, it aims to supply 100 million doses in the first half of 2021. Unlike Pfizer and Moderna, Johnson & Johnson’s Janssen vaccine can be stored for at least three months at 36-46 degrees Fahrenheit, compatible with standard vaccine distribution channels, the company said.

It has shown to be 66% effective overall in preventing moderate to severe COVID-19 four weeks after the shot is administered. Johnson & Johnson said the vaccine was 72% effective in the United States, compared to 66% in Latin America and 57% in South Africa.

However, the vaccine is 85% effective in preventing severe forms of COVID-19. And the efficacy of the treatment increased over time, the company said, with no cases in vaccinated participants after 49 days.


Recommended For You

About the Author: News Updates